Pregnancy registry for hepatitis C treatment timing
Part of Digestive system, Infections clinical trials.
This study is a pregnancy registry that collects information about people who have hepatitis C during pregnancy and took hepatitis C medicines early in pregnancy. It aims to better understand the safety and outcomes of treatment around conception.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently pregnant (or recently were) and your pregnancy timing is documented (from last period date or an ultrasound).
- You have a confirmed chronic hepatitis C infection during or before pregnancy (a positive hepatitis C blood test for the virus).
- You took hepatitis C medicine called a DAA within 30 days of your estimated conception date, before your pregnancy ended in delivery or loss.
- The hepatitis C medicine you took must be one of the specific approved DAA options listed by the study.
- You did NOT take hepatitis C medicines that include ribavirin or interferon during that early pregnancy time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called glecaprevir/pibrentasvir for pregnant women with hepatitis C, with or without HIV. It aims to see how the medicine works in the body and if it is safe during pregnancy.
This study tests whether treating hepatitis C during pregnancy is feasible and acceptable for pregnant women who have a history of drug use. If you qualify, you may receive treatment that could help protect your health and your baby's health.
This trial tests a hepatitis B medicine called TAF in pregnant women who need antiviral treatment. It helps protect both mom and baby from complications of the virus.
This study compares two antiviral medications (TAF and TDF) in pregnant women with hepatitis B to see which is safer and more effective during pregnancy and for the baby's health.
This registry is for people in Taiwan who have received direct-acting antiviral (DAA) treatment for hepatitis C. It collects health information to better understand outcomes and care, and you can join if you agree to participate and sign consent.
This trial tests if TAF is safer and as effective as TDF for pregnant women with high hepatitis B viral loads to prevent passing the virus to their babies. You may qualify if you are pregnant, between 20-28 weeks, and have high viral levels.
Hear when a new Hepatitis C trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.